Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies



Status:Completed
Conditions:Cancer, Lymphoma, Neurology
Therapuetic Areas:Neurology, Oncology
Healthy:No
Age Range:18 - 89
Updated:12/22/2017
Start Date:October 2010
End Date:April 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center

The purpose of this study is to assess the feasibility of a 60 minute rapid infusion
rituximab protocol in the institution's outpatient infusion center.


Inclusion Criteria:

- Age 18-89

- Diagnosis of indolent or intermediate grade B-cell malignancy

- Patients receiving rituximab-based therapy at a dose of 375mg/m2, regardless of weight

- First dose given within 3 months of the second dose

- Infusion scheduled for outpatient administration at The Arthur G. James Cancer
Hospital and Richard J. Solove Research Institute

Exclusion Criteria:

- Diagnosis of aggressive lymphoma

- Absolute lymphocyte count > 10 x 103 cells/µL

- New York Heart Association (NYHA) classification Grade II or greater congestive heart
failure

- Enrolled on another clinical trial

- Allergy to murine-containing medications

- Grade III or IV hypersensitivity reaction during the initial infusion of rituximab

- Prisoners

- Pregnant women

- Mentally or physically unable to give consent
We found this trial at
1
site
Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
?
mi
from
Columbus, OH
Click here to add this to my saved trials